Vor Biopharma (NASDAQ:VOR) Upgraded at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Vor Biopharma (NASDAQ:VOR) to a strong-buy rating in a research note released on Sunday morning,Zacks.com reports.

Several other analysts have also recently weighed in on the company. TD Cowen assumed coverage on Vor Biopharma in a report on Wednesday, December 17th. They issued a “buy” rating on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday, December 19th. Citigroup assumed coverage on shares of Vor Biopharma in a research note on Friday, January 9th. They issued a “buy” rating and a $50.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, January 21st. Finally, Wells Fargo & Company assumed coverage on shares of Vor Biopharma in a research note on Thursday, March 19th. They issued an “overweight” rating and a $30.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $50.67.

Vor Biopharma Stock Performance

NASDAQ:VOR opened at $17.84 on Friday. The firm has a market capitalization of $185.71 million, a price-to-earnings ratio of -0.05 and a beta of 1.99. Vor Biopharma has a 52-week low of $2.62 and a 52-week high of $65.80. The stock has a fifty day moving average of $14.19 and a 200 day moving average of $17.73.

Hedge Funds Weigh In On Vor Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the stock. RA Capital Management L.P. boosted its stake in shares of Vor Biopharma by 172.7% during the fourth quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock valued at $70,697,000 after purchasing an additional 3,422,697 shares during the period. Fcpm Iii Services B.V. increased its stake in shares of Vor Biopharma by 852.8% in the fourth quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock worth $47,315,000 after buying an additional 3,237,714 shares during the period. Frazier Life Sciences Management L.P. purchased a new position in shares of Vor Biopharma in the fourth quarter worth $33,275,000. Paradigm Biocapital Advisors LP bought a new stake in Vor Biopharma during the 4th quarter valued at $22,890,000. Finally, NEXTBio Capital Management LP bought a new stake in Vor Biopharma during the 4th quarter valued at $13,080,000. 97.29% of the stock is currently owned by institutional investors.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).